Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 1,300 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,115 shares of the biopharmaceutical company’s stock after purchasing an additional 1,300 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Alnylam Pharmaceuticals were worth $6,851,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of ALNY. Blue Trust Inc. grew its stake in shares of Alnylam Pharmaceuticals by 431.0% in the third quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 375 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 62.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 161 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $30,260,000. Ballentine Partners LLC grew its stake in shares of Alnylam Pharmaceuticals by 10.4% in the third quarter. Ballentine Partners LLC now owns 1,534 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 145 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Alnylam Pharmaceuticals by 56.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,454 shares of the biopharmaceutical company’s stock worth $1,775,000 after purchasing an additional 2,323 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,986 shares of company stock valued at $20,397,849. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $248.94 on Tuesday. The company has a market capitalization of $32.23 billion, a P/E ratio of -114.72 and a beta of 0.35. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a 50 day moving average of $254.24 and a 200 day moving average of $262.90. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Sanford C. Bernstein lowered their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Piper Sandler restated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Scotiabank lowered their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $303.83.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.